{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:57:16Z","timestamp":1792051036351,"version":"4.4.0"},"reference-count":66,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 DC005356"],"award-info":[{"award-number":["T32 DC005356"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA046592"],"award-info":[{"award-number":["P30-CA046592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005193","name":"American Academy of Otolaryngology-Head and Neck Surgery","doi-asserted-by":"publisher","award":["Translational Innovator Award"],"award-info":[{"award-number":["Translational Innovator Award"]}],"id":[{"id":"10.13039\/100005193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Organ preservation protocols are commonly used as first line therapy for advanced laryngeal cancer. Recurrence thereafter is associated with poor survival. The aim of this study is to identify genetic alterations associated with survival among patients with recurrent laryngeal cancer undergoing salvage laryngectomy. Sixty-two patients were sequenced using a targeted panel, of which twenty-two also underwent transcriptome sequencing. Alterations were grouped based on biologic pathways and survival outcomes were assessed using Kaplan-Meier analysis and multivariate cox regression. Select pathways were evaluated against The Cancer Genome Atlas (TCGA) data. Patients with mutations in the Oxidation pathway had significantly worse five-year disease specific survival (1% vs. 76%, p = 0.02), while mutations in the HN-Immunity pathway were associated with improved five-year disease specific survival (100% vs. 62%, p = 0.02). Multivariate analysis showed mutations in the Oxidation pathway remained an independent predictor of disease specific survival (HR 3.2, 95% CI 1.1\u20139.2, p = 0.03). Transcriptome analysis of recurrent tumors demonstrated that alterations in the Oxidation pathway were associated a positive Ragnum hypoxia signature score, consistent with enhanced pathway activity. Further, TCGA analyses demonstrated the prognostic value of oxidation pathway alterations in previously untreated disease. Alterations in the Oxidation pathway are associated with survival among patients with recurrent laryngeal cancer. These prognostic genetic biomarkers may inform precision medicine protocols and identify putatively targetable pathways to improve survival in this cohort.<\/jats:p>","DOI":"10.3390\/cancers12113081","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T20:51:00Z","timestamp":1603399860000},"page":"3081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"12","author":[{"given":"Molly E.","family":"Heft Neal","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva D.","family":"Bhangale","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Birkeland","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of California Davis, Sacramento, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan B.","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Shuman","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Rosko","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3555","authenticated-orcid":false,"given":"Paul L.","family":"Swiecicki","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"},{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Spector","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-1111","authenticated-orcid":false,"given":"J. Chad","family":"Brenner","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA"},{"name":"Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf, G.T., Fisher, S.G., Hong, W.K., Hillman, R., Spaulding, M., Laramore, G.E., Endicott, J.W., McClatchey, K., and Henderson, W.G. (1991). Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer. N. Engl. J. Med., 324, 1685\u20131690.","DOI":"10.1056\/NEJM199106133242402"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.radonc.2013.08.016","article-title":"A systematic review of current and emerging approaches in the field of larynx preservation","volume":"110","author":"Denaro","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.oraloncology.2018.11.022","article-title":"Salvage laryngectomy following organ-preservation therapy\u2014An evidence-based review","volume":"88","author":"Silverman","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/hed.24918","article-title":"Predictors of survival after total laryngectomy for recurrent\/persistent laryngeal squamous cell carcinoma","volume":"39","author":"Birkeland","year":"2017","journal-title":"Head Neck"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E1962","DOI":"10.1002\/hed.24355","article-title":"Salvage total laryngectomy after external-beam radiotherapy: A 20-year experience","volume":"38","author":"Sandulache","year":"2016","journal-title":"Head Neck"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.oraloncology.2011.02.002","article-title":"Salvage laryngectomy: Oncological and functional outcome","volume":"47","author":"Kuik","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005537-200003001-00001","article-title":"Salvage Surgery for Patients With Recurrent Squamous Cell Carcinoma of the Upper Aerodigestive Tract: When Do the Ends Justify the Means?","volume":"110","author":"Goodwin","year":"2000","journal-title":"Laryngoscope"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/hed.24860","article-title":"Prognostic indicators and survival in salvage surgery for laryngeal cancer","volume":"39","author":"Fletcher","year":"2017","journal-title":"Head Neck"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lary.26782","article-title":"Elucidation of salvage laryngectomy pathologic and clinical variables to guide further treatment intensification investigation","volume":"128","author":"Scharpf","year":"2017","journal-title":"Laryngoscope"},{"key":"ref_11","first-page":"527","article-title":"Primary and salvage total laryngectomy. Influential factors, complications, and survival","volume":"20","author":"Stankovic","year":"2015","journal-title":"J. BUON Off. J. Balk. Union Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/coa.12726","article-title":"Prognostic factors for survival after salvage total laryngectomy following radiotherapy or chemoradiation failure: A 10-year retrospective longitudinal study in eastern Denmark","volume":"42","author":"Wulff","year":"2016","journal-title":"Clin. Otolaryngol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hed.25444","article-title":"Mutational profiles of persistent\/recurrent laryngeal squamous cell carcinoma","volume":"41","author":"Smith","year":"2018","journal-title":"Head Neck"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1017\/S0022215106001150","article-title":"Changes in expression of p53, proliferating cell nuclear antigen and bcl-2 in recurrent laryngeal cancer after radiotherapy","volume":"120","author":"Lee","year":"2006","journal-title":"J. Laryngol. Otol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69641","DOI":"10.18632\/oncotarget.18751","article-title":"A potential panel of two-long non-coding RNA signature to predict recurrence of patients with laryngeal cancer","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.21873\/anticanres.11081","article-title":"Radiotherapy-associated Furin Expression and Tumor Invasiveness in Recurrent Laryngeal Cancer","volume":"36","author":"Lee","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_17","first-page":"4806","article-title":"Signature microRNAs and long noncoding RNAs in laryngeal cancer recurrence identified using a competing endogenous RNA network","volume":"19","author":"Tang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_18","first-page":"576","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Network","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2019.09.016","article-title":"\u201cNRF2 addiction\u201d in lung cancer cells and its impact on cancer therapy","volume":"467","author":"Hammad","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","article-title":"Role of KEAP1\/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance","volume":"7","author":"Jeong","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2014.604","article-title":"The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer","volume":"112","author":"Ragnum","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hed.1074","article-title":"Prognosis of patients with recurrent laryngeal carcinoma","volume":"23","author":"Brenner","year":"2001","journal-title":"Head Neck"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/archotol.1997.01900040056009","article-title":"Surgical salvage after radiotherapy for advanced laryngopharyngeal carcinoma","volume":"123","author":"Davidson","year":"1997","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ijrobp.2013.12.016","article-title":"Development of TRAIL Resistance by Radiation-Induced Hypermethylation of DR4 CpG Island in Recurrent Laryngeal Squamous Cell Carcinoma","volume":"88","author":"Lee","year":"2014","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0194599813486257","article-title":"Salvage Laryngectomy in Patients with Recurrent Laryngeal Cancer in the Setting of Nonoperative Treatment Failure","volume":"149","author":"Li","year":"2013","journal-title":"Otolaryngol. Neck Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1007\/s13277-016-4991-4","article-title":"Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma","volume":"37","author":"Bednarek","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/lary.24245","article-title":"Biomarkers in advanced larynx cancer","volume":"124","author":"Bradford","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/mc.22808","article-title":"Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation","volume":"57","author":"Byzia","year":"2018","journal-title":"Mol. Carcinog."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archotol.134.4.363","article-title":"Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer","volume":"134","author":"Kumar","year":"2008","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sato, E., Nakayama, K., Razia, S., Nakamura, K., Ishikawa, M., Minamoto, T., Ishibashi, T., Yamashita, H., Iida, K., and Kyo, S. (2018). ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061710"},{"key":"ref_33","first-page":"1","article-title":"CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma","volume":"18","author":"Weller","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13402-017-0367-z","article-title":"Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K\/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer","volume":"41","author":"Starska","year":"2018","journal-title":"Cell. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1080\/15384101.2018.1496756","article-title":"\u201cKeaping\u201d a lid on lung cancer: The Keap1-Nrf2 pathway","volume":"17","author":"Best","year":"2018","journal-title":"Cell Cycle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and Pathological Characteristics ofKEAP1- andNFE2L2-Mutated Non\u2013Small Cell Lung Carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_37","first-page":"91","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wolf, B., G\u00f6bel, G., Hackl, H., and Fiegl, H. (2016). Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2840-x"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"(2014). The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nat. Cell Biol., 511, 543\u2013550.","DOI":"10.1038\/nature13385"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"(2012). The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nat. Cell Biol., 489, 519\u2013525.","DOI":"10.1038\/nature11404"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/path.2653","article-title":"Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin","volume":"220","author":"Kim","year":"2009","journal-title":"J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","first-page":"6819","article-title":"Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer","volume":"35","author":"Aso","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1038\/s41388-018-0300-6","article-title":"ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors","volume":"37","author":"Berns","year":"2018","journal-title":"Oncogene"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.28705","article-title":"Exome sequencing reveals frequent inactivating mutations inARID1A, ARID1B, ARID2andARID4Ain microsatellite unstable colorectal cancer","volume":"135","author":"Cajuso","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ajhg.2015.08.002","article-title":"Chromatin-Remodeling-Factor ARID1B Represses Wnt\/beta-Catenin Signaling","volume":"97","author":"Vasileiou","year":"2015","journal-title":"Am. J. Human Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ng.2291","article-title":"Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators","volume":"44","author":"Fujimoto","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nm.3480","article-title":"ARID1B is a specific vulnerability in ARID1A-mutant cancers","volume":"20","author":"Helming","year":"2014","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54757-z","article-title":"Targeting ARID1A-mutant colorectal cancer: Depletion of ARID1B increases radiosensitivity and modulates DNA damage response","volume":"9","author":"Niedermaier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jcp.54.3.201","article-title":"Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis","volume":"54","author":"Franchi","year":"2001","journal-title":"J. Clin. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-014-0428-9","article-title":"Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer","volume":"15","author":"Nadauld","year":"2014","journal-title":"Genome Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/0008-5472.CAN-17-3303","article-title":"Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer","volume":"78","author":"Sakai","year":"2017","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13046-018-0764-9","article-title":"Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways","volume":"37","author":"Zhou","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3390\/cancers7040900","article-title":"Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches","volume":"7","author":"Allen","year":"2015","journal-title":"Cancers"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002371-199705000-00001","article-title":"Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer Therapy","volume":"20","year":"1997","journal-title":"J. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.12.003","article-title":"Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent\/recurrent laryngeal squamous cell carcinoma","volume":"77","author":"Hoesli","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00262-018-2256-3","article-title":"Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma","volume":"68","author":"Mann","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/jamaoto.2019.2427","article-title":"Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma","volume":"145","author":"Spector","year":"2019","journal-title":"JAMA Otolaryngol. Neck Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E1646","DOI":"10.1002\/hed.24292","article-title":"Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing","volume":"38","author":"Tillman","year":"2016","journal-title":"Head Neck"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopha.2017.10.129","article-title":"Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer","volume":"97","author":"Jeddi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:08Z","timestamp":1760178368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":66,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113081"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113081","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}